Recurrent Melanoma Terminated Phase 1 Trials for Vemurafenib (DB08881)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01835184Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By SurgeryTreatment